South African Thoracic Society statement on obstructive airways disease and COVID-19

Summary

- Asthmatics do not appear to have increased susceptibility to COVID-19.
- Uncontrolled severe asthma may be associated with worsened COVID-19 outcomes, especially in asthmatics managed with oral corticosteroids.
- Risk mitigation measures such as hand hygiene, social distancing and wearing of face masks must be observed at all times.
- Asthma should be managed as outlined in local and international guidelines.
- Ensure an adequate supply of medication, and inhaled corticosteroids should not be withdrawn.
- Chronic obstructive pulmonary disease (COPD) is associated with severe COVID-19 disease and poor outcomes.
- Maintenance of background medication is important to avoid exacerbations of COPD.
- Vaccination against influenza is strongly advised for all patients with asthma and COPD.
- Vaccination against pneumococcal infection is advisable for patients with COPD.
- Patients with obstructive airway disease on oral corticosteroids and/or with impaired lung function should take stringent safety precautions.

This statement will be updated when more data become available.

Asthma

Asthmatics do not appear to have increased susceptibility to COVID-19.[i,ii] However, when asthmatics contract COVID-19, they may have a worse outcome. Thus, while asthma was not documented as a risk factor/underlying comorbidity for COVID-19 infection in earlier studies, some more recent studies, particularly from the USA, have shown that asthma may be a significant comorbid condition.[2,3] Furthermore, asthma was also found to be relatively common among intensive care unit cases with COVID-19 and in patients who died. Therefore, while mild to moderate asthma that is well controlled may not be a risk factor for COVID-19, people with uncontrolled and severe asthma, those receiving repeated or regular doses of oral corticosteroids (OCS) and those with underlying structural lung damage may be at risk of more severe COVID-19.

Recently published data from the UK primary care and COVID-19 system notification databases have indicated that asthma (without corticosteroid use) was not associated with higher mortality when adjusting for confounders in 10 926 COVID-19-associated deaths in the UK.[4] Asthma with recent use of OCS was associated with higher mortality compared with non-asthmatics when fully adjusted for other variables (hazard ratio (95% confidence interval) 1.13 (1.01 - 1.26)).[5] By contrast, the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) study reported that 14% of hospitalised patients with asthma have no increased risk of death.[5] Data from Spain[6] suggest that a few patients with asthma were infected with SARS-CoV-2 and this was not associated with asthma exacerbation.

Regarding other asthma phenotypes and patients from other settings, there is little data available, and thus recommendations cannot be made. Few asthma patients are recorded in published cohorts of SARS-CoV-2 infections in China, and it has not been linked to poor outcomes.[6,7] Although data from the previous severe acute respiratory syndrome and Middle East respiratory syndrome outbreaks did not demonstrate any increased risk of infection nor severe disease in asthmatics, this may be different for COVID-19, and further data are awaited.[8,9] Data from previous influenza outbreaks and the 2009 H1N1 pandemic suggest that asthma was associated with hospitalisation,[10] but interestingly, protective for mortality.[11]

Based on these limited data, severe asthmatics (especially if receiving OCS) seem to be at higher risk of death than non-asthmatics. There is no evidence to suggest that inhaled steroids should be stopped as they are protective against asthma exacerbations.[12] Inhaled or OCS should not be withheld if indicated to treat exacerbations of asthma.

Chronic obstructive pulmonary disease

Current evidence summarised in two meta-analyses indicate that chronic obstructive pulmonary disease (COPD) patients are at a significantly higher risk of severe COVID-19 and adverse outcomes. Lippi et al.[14] reported on 1 592 patients and demonstrated a significant association between COPD and poor outcomes in COVID-19 (odds ratio 5.69 (2.49 - 13.00)). The second meta-analysis included 15 studies with 2 473 patients. The patients with COPD had a relative risk of 1.88 (1.4 - 2.4) for severe COVID-19 compared with non-COPD patients.[15] These data provide sufficient evidence establishing an association between COPD and risk of severe COVID-19. Tobacco smoking has also been associated with severe COVID-19 and adverse outcomes.[16] It is unclear, however, if smoking is an additive risk factor in addition to COPD. It is worth noting that data are discordant and in both the UK[17] and China,[18] COPD did appear to confer increased risk of death among hospitalised and confirmed cases, respectively.[19,20]

Influenza and pneumococcal vaccination are recommended as well as a regular supply of background medication.[21] Inhaled steroids are a risk factor for bacterial pneumonia and should be avoided unless indicated[22] and where dual bronchodilators are not accessible.
Afr J Thoracic Crit Care Med 2020;26(3):117-118. https://doi.org/10.7196/AJTCCM.2020.v26i3.111

1. Morais-Almeida M, Pite H, Aguiar R, et al. Asthma and the coronavirus disease 2019 pandemic: A literature review. Int Arch Allergy Immunol 2020, 181(9):680-688. https://doi.org/10.1159/000509507
2. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5,701 patients hospitalised with COVID-19 in the New York City area. JAMA 2020;323(20):2052-2059. https://doi.org/10.1001/jama.2020.6775
3. Rosenberg ES, Dufort EM, Blegen DS, et al. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State – March 2020. Clin Infect Dis 2020 (epub 8 May 2020). https://doi.org/10.1093/cid/ciaa549
4. Williamson EM, Walker AJ, Bhakkar K, et al. Factors associated with COVID-19 related death using OpenSAFELY. Nature 2020;584(7821):430-437. https://doi.org/10.1038/s41586-020-2521-4
5. International Severe Acute Respiratory and Emerging Infection Consortium. COVID-19 clinical resources 2020. https://isarc.tghn.org/covid-19-clinical-research-resources/(accessed 11 September 2020).
6. Halpin DMG, Furer R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 2020;8(5):436-438. https://doi.org/10.1016/S2213-2601(20)30167-3
7. Zhang J, Dong X, Cao YI, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 (epub 23 February 2020). https://doi.org/10.1111/all.14238
8. Nam HS, Park JW, Ki M, et al. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Int J Infect Dis 2017;58:37-42. https://doi.org/10.1016/j.ijid.2017.02.008
9. Kim KH, Tandi TE, Choi JW, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: Epidemiology, characteristics and public health implications. J Hosp Infect 2017;95(2):207-213. https://doi.org/10.1016/j.jhin.2016.10.008
10. Chen CY, Lee CH, Liu CY, et al. Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. J Chin Med Assoc 2015;78(4):160-165. https://doi.org/10.1016/j.jcma.2015.02.004
11. Ko SE, Lee TY, Huang CC, et al. Severe acute respiratory syndrome: Prognostic implications of chest radiographic findings in 52 patients. Radiology 2004;233(1):173-181. https://doi.org/10.1148/radiol.2331031547
12. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20):1986-1994. https://doi.org/10.1056/NEJMoa030685
13. Veerapandian R, Snyder JD, Samarasinge AE. Influenza in asthmatics: For better or for worse? Front Immunol 2018;9:1843. https://doi.org/10.3389/fimmu.2018.01843
14. Van Kerkhove MD, Vandemeulebroeke KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: A global pooled analysis. PLoS Med 2011;8(7):e1001053. https://doi.org/10.1371/journal.pmed.1001053
15. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: A systematic review and clinical perspective. Eur Respir J 2020;50(1):200209. https://doi.org/10.1162/NEJMoa2006106
16. Alqatami JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis. PLoS One 2020;15(5):e0233147. https://doi.org/10.1371/journal.pone.0233147
17. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020;18(March):20. https://doi.org/10.18332/tid/119324
18. Deng G, Yin M, Chen X, et al. Clinical determinants for fatality of 44 672 patients with COVID-19. Crit Care 2020;24(11):179. https://doi.org/10.1186/s13054-020-02902-w
19. Docherty K, Butt J, de Boer R, et al. Excess deaths during the COVID-19 pandemic: An international comparison. medRxiv 2020:2020.04.21.20073114. https://doi.org/10.1101/2020.04.21.20073114
20. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease – 2020 report. https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (accessed 11 September 2020).